2026
Mjali A, Audia S, Miyakawa Y, Ghanima W. Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways. Expert Rev Hematol. 2026 May 13:1-12. doi: 10.1080/17474086.2026.2672113.
Tsykunova G, Kristiansen EB, Tvedt THA, Frederiksen H, Christiansen CF, Linder M, Bahmanyar S, Ghanima W. Factors associated with response to rituximab in patients with immune thrombocytopenia. Hemasphere. 2026 Apr 28;10(5). doi: 10.1002/hem3.70373.
Ghanima W, Hou Y. Anti-CD38 therapy in immune thrombocytopenia (ITP). Br J Haematol. 2026 Apr 23. doi: 10.1111/bjh.70493.
Liu Z, Rebetz J, Garabet L, Ghanima W, Xu P, Wadenvik H, Provan D, Kapur R, Semple JW. MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia. Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70485.
Garabet L, Ghanima W. Thrombosis in immune thrombocytopenia. Br J Haematol. 2026 Jun;208(6):1924-1927. doi: 10.1111/bjh.70474.
Vijenthira A, Frederiksen H, Sholzberg M.. The association of thrombocytopenia with hematologic malignancy. British Journal of Haematology, 2026, Online ahead of print. PMID: 42031689
Rasmussen M, Mannering N, Frederiksen H. Incidence of Systemic Lupus Erythematosus in patients first diagnosed with Immune Thrombocytopenia: A nationwide Danish study. British Journal of Haematology, 2026, 208(3): 1144-1147. PMID: 41431208
2025
Ghanima W, Lucas Boronat FJ, Carrai V, Rackwitz S. Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports. Hematology. 2025 Dec;30(1):2456687. doi: 10.1080/16078454.2025.2456687.
Garabet L, Rangberg A, Eriksson AM, Jonassen CM, Teruel-Montoya R, Lozano ML, Martinez C, Pettersen HH, Mathisen ÅB, Tjønnfjord E, Tran H, Brodin E, Tsykunova G, Gebhart J, Bussel J, Ghanima W. MicroRNA-199a-5p may be a diagnostic biomarker of primary ITP. Br J Haematol. 2025 Jan 7. doi: 10.1111/bjh.19987.
Kuter DJ, Ghanima W. Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy. 2025 Aug 11:1-16. doi: 10.1080/1750743X.2025.2545170.
Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjonnfjord E, Munthe LA, Drivet E, Kared H, Sørvoll IH, Ahlen MT, Mahevas M, Michel M, Bussel JB, Kuter DJ, Tvedt THA, Ghanima W. Safety and Efficacy of Daratumumab in Immune Thrombocytopenia. Blood Adv. 2025 Aug 5:bloodadvances.2025017279. doi: 10.1182/bloodadvances.2025017279.
Garabet L, Ghanima W, Bussel J, Tran H, Brodin E, Mathisen ÅB, Lae S, Le MS, Hillarp A, Henriksson CE. Increased ultra-large von Willebrand factor multimers in immune thrombocytopenia. Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20205.